What is Hinge Bio?
Hinge Bio, Inc. is a biotechnology firm pioneering advancements in antibody-based therapeutics through its proprietary GEM-DIMER Platform. This technology facilitates the creation of novel therapeutics with enhanced multivalency and multispecificity, aiming for superior safety and efficacy in disease treatment. The company is driven by an experienced leadership team focused on achieving successful drug development outcomes and is actively expanding its ranks with professionals passionate about next-generation therapeutics.
How much funding has Hinge Bio raised?
Hinge Bio has raised a total of $30M across 1 funding round:
Series A
$30M
Series A (2025): $30M with participation from Lightswitch Capital, Point72, InVivium Capital, and Ridgeback Capital
Key Investors in Hinge Bio
Lightswitch Capital
Lightswitch Capital is dedicated to empowering entrepreneurs by investing in and partnering with private healthcare companies, focusing on long-term growth and providing essential resources and expert advice.
Point72
Point72 is a private investment management firm established in 1992, managing various private investment funds across different asset classes.
InVivium Capital
InVivium Capital is a venture capital fund specializing in transformative life sciences and healthcare innovations, aiming to support groundbreaking advancements that create meaningful changes in health and care.
What's next for Hinge Bio?
The substantial enterprise-level funding positions Hinge Bio for significant scaling and progression towards clinical development. This capital infusion is expected to accelerate the advancement of its GEM-DIMER Programs, potentially enabling the company to move preclinical data into human trials and further solidify its market position. The strategic investment signals a strong belief in Hinge Bio's potential to disrupt the therapeutic landscape.
See full Hinge Bio company page
